Remove 2029 Remove Disease Remove Marketing
article thumbnail

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

FDA Law Blog: Biosimilars

Tobolowsky — The Rare Pediatric Disease Priority Review Voucher program has had a bit of a tumultuous history in its 12 short years of existence. Over 50 rare pediatric disease priority review vouchers have been awarded to date. We heard and felt the anxiety from many of our clients about the uncertainty this caused.

Disease 64
article thumbnail

Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines

The Pharma Data

650 million fixed rate notes, due April 2029, bearing interest at an annual rate of 1.250%. million patients, provided with essential medicines by the global health unit, for the treatment of non-communicable diseases in 40 of the world’s poorest countries, between 2022 and 2026.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS

The Pharma Data

Amgen (NASDAQ:AMGN) today announced the issuance of its inaugural $750 million green bond, with a 3.000% semi-annual coupon and maturing in 2029, to advance the environmental goals that are part of Amgen’s environmental, social and governance (ESG) framework.

article thumbnail

What is the largest CRO in the US?

Vial

By geographical region, the global CRO services market in 2023 was dominated by North America. Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market.

article thumbnail

BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes

The Pharma Data

Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

article thumbnail

Lilly Announces the Pricing Terms of Its Cash offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities

The Pharma Data

3.375% Notes due 2029 532457 BV9 12 1.250% due August 15, 2031 1.321% 15 bps $1,130.16 and Citigroup Global Markets Inc. Treasury Security Reference Yield Fixed Spread Total Consideration (1)(2) 4.150% Notes due 2059 532457 BU1 1 (3) 2.375% due May 15, 2051 1.865% 80 bps $1,347.88 Lilly has retained BofA Securities, Inc.

Disease 52
article thumbnail

Lilly Announces the first Tender Results of Its Pending Cash offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059

The Pharma Data

and Citigroup Global Markets Inc. toll-free at +1 (888) 292-0070 or collect at +1 (980) 387-3907 or to Citigroup Global Markets Inc. As a result, tendered notes may not be withdrawn, except in certain limited circumstances where additional withdrawal rights are required by law. Lilly has retained BofA Securities, Inc.